ArticleJournal of clinical medicine research2025
Clinical Effects of the Concurrent Ingestion of Rosuvastatin and Magnesium Oxide: A Multicenter, Randomized, Parallel-Group Trial.
Article in Journal of clinical medicine research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiovascular disease (CVD) remains a leading global cause of mortality. Statins, particularly rosuvastatin (RSV), are widely used to reduce low-density lipoprotein cholesterol (LDL-C) level and prevent atherosclerotic CVD. RSV is highly liver-selective, hydrophilic, and primarily transported via organic anion transport proteins, rendering it less prone to cytochrome P450-mediated drug interactions. However, the concurrent use with magnesium oxide (MgO), a common antacid and laxative, has been shown to decrease RSV absorption by up to 50%, raising concerns regarding the clinical efficacy of RSV in patients taking MgO. Methods: This multicenter, randomized, parallel-group comparative trial included outpatients prescribed both RSV and MgO at Fukuoka University Chikushi and Fukuoka Tokushukai Hospitals. Patients were randomly assigned to the control group with simultaneous administration or the intervention group with staggered administration of MgO at least 2 h after RSV. Data on demographics and serum levels of LDL-C, total cholesterol, high-density lipoprotein cholesterol, and triglycerides were collected at baseline and 12 weeks after study initiation. Medication adherence was monitored using a self-reported medication checklist, and patients with ≥ 80% compliance were included in the final analysis. Results: A total of 45 patients, including 25 and 20 patients in the control and intervention groups, respectively, completed the study. The median ages were 78 and 76 years in the control and intervention groups, respectively. The baseline demographics and clinical parameters, including LDL-C, were not significantly different between the two groups. After 12 weeks, the rate of change in LDL-C level was not significantly between the control and intervention groups (P = 0.9091). Conclusion: The concurrent use of RSV and MgO did not significantly impact the reduction in LDL-C levels compared with the staggered administration. Simplifying administration without altering efficacy can improve medication adherence, particularly in elderly patients and those with polypharmacy, by reducing treatment complexity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.